Topics

Eyenovia Inc. Company Profile

21:32 EDT 21st September 2019 | BioPortfolio

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases. For more information, visit www.eyenoviabio.com.


News Articles [33 Associated News Articles listed on BioPortfolio]

Eyenovia nets $11.5mm via FOPO

Ophthalmic firm Eyenovia Inc. netted $11.5mm via a follow-on offering of 4.39mm common shares at $2.78 each. The company will use the funds for Phase III trials of its MicroProst (latanoprost) for chr...

Eyenovia nets $13.2mm via FOPO

Ophthalmic firm Eyenovia Inc. netted $13.2mm via a follow-on offering of 5.05mm common shares (including full exercise of the overallotment) at $2.78 each. The company will use the funds for Phase III...

Eyenovia Enrolls First Patient in Phase 3 Study for Progressive Myopia

Eyenovia (NASDAQ:EYEN) has announced it has initiated its MicroPine Phase 3 program with the first patient enrolled in its CHAPERONE study. As quoted in the press release: The CHAPERONE study is a U.S...

Eyenovia Announces FDA Acceptance of IND Application for MicroPine to Reduce the Progression of Myopia

Eyenovia (NASDAQ:EYEN) has announced that the US Food and Drug Administration has accepted its Investigational New Drug (IND) application to initiate the company’s CHAPERONE Phase III study to r...

Eyenovia sees bright future for first Phase 3 trial of its eye disorder drug

Eyenovia (NASDAQ:EYEN) CEO Dr. Sean Ianchulev tells Proactive Investors the New York-based company, which recently announced fourth-quarter results, is also advancing trials for its eye disorder dru...

Eyenovia to Participate in Two Upcoming Investor Conferences

NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its paten...

Eyenovia, Inc. Announces Closing of Public Offering

NEW YORK, July 15, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patent...

Eyenovia to Present at Two Upcoming Investor Conferences

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Eyenovia MiDD Usability Study

This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)

Companies [2 Associated Companies listed on BioPortfolio]

Eyenovia Inc.

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for mic...

Eyenovia, Inc.

More Information about "Eyenovia Inc." on BioPortfolio

We have published hundreds of Eyenovia Inc. news stories on BioPortfolio along with dozens of Eyenovia Inc. Clinical Trials and PubMed Articles about Eyenovia Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eyenovia Inc. Companies in our database. You can also find out about relevant Eyenovia Inc. Drugs and Medications on this site too.

Quick Search

Relevant Topic

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...


Corporate Database Quicklinks



Searches Linking to this Company Record